Gordon J Mills

US Patent:

7871775, Jan 18, 2011

Filed:

Dec 17, 2007

Appl. No.:

12/002783

Inventors:

Edwin Clark - Ashland MA, US
Tallessyn Grenfell-Lee - Cambridge MA, US
Karen Lu - Houston TX, US
Lynn Hartmann - Rochester MN, US
Jeffrey L. Brown - Arlington MA, US
Gordon B. Mills - Houston TX, US

Assignee:

Millennium Pharmaceuticals, Inc - Cambridge MA
Mayo Foundation for Medical Edication and Research - Rochester MN
Board of Regents, The University of Texas System - Austin TX

International Classification:

C12Q 1/68

US Classification:

435 6, 536 231

Abstract:

The present invention is directed to the identification of markers that can be used to determine whether tumors are sensitive or resistant to a therapeutic agent. The present invention is also directed to the identification of therapeutic targets. The invention features a number of “sensitivity markers. ” These are markers that are expressed in most or all cell lines that are sensitive to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are resistant to treatment with that agent. The invention also features a number of “resistance markers. ” These are markers that are expressed in most or all cell lines that are resistant to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are sensitive to treatment with that agent. The invention also features marker sets that can predict patients that are likely to respond or not to respond to an agent.

US Patent:

20020182619, Dec 5, 2002

Filed:

Nov 8, 2001

Appl. No.:

10/035415

Inventors:

James Lillie - Natick MA, US
Gordon Mills - Houston TX, US
John Lee - Somerville MA, US

Assignee:

Millennium Pharmaceuticals, Inc. - Boston MA

International Classification:

C12Q001/68
G01N033/574

US Classification:

435/006000, 435/007230

Abstract:

The invention relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating human ovarian cancers. A variety of markers are provided, wherein changes in the levels of expression of one or more of the markers is correlated with the presence of ovarian cancer.

US Patent:

20030087250, May 8, 2003

Filed:

Mar 14, 2002

Appl. No.:

10/097340

Inventors:

John Monahan - Walpole MA, US
Manjula Gannavarapu - Acton MA, US
Sebastian Hoersch - Arlington MA, US
Shubhangi Kamatkar - Newton MA, US
Steven Kovats - Wilmington MA, US
Rachel Meyers - Newton MA, US
Michael Morrisey - Brighton MA, US
Peter Olandt - Watertown MA, US
Ami Sen - Framingham MA, US
Petter Veiby - Westborough MA, US
Gordon Mills - Houston TX, US
Robert Bast - Houston TX, US
Karen Lu - Houston TX, US
Rosemarie Schmandt - Houston TX, US
Xumei Zhao - Wayland MA, US
Karen Glatt - Natick MA, US

Assignee:

Millennium Pharmaceuticals, Inc. - Cambridge MA

International Classification:

C12Q001/68
G01N033/574

US Classification:

435/006000, 435/007230

Abstract:

The invention relates to newly discovered nucleic acid molecules and proteins associated with ovarian cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human ovarian cancers are provided.

US Patent:

20030124128, Jul 3, 2003

Filed:

Jun 21, 2002

Appl. No.:

10/177293

Inventors:

James Lillie - Natick MA, US
Manjula Gannavarapu - Acton MA, US
Karen Glatt - Natick MA, US
Sebastian Hoersch - Arlington MA, US
Shubhangi Kamatkar - Newton MA, US
Maureen Mertens - Stow MA, US
John Monahan - Walpole MA, US
Vickesh Myer - Harvard MA, US
Youzhen Wang - Newton MA, US
Yongyao Xu - Belmont MA, US
Xumei Zhao - Wayland MA, US
Rachel Meyers - Newton MA, US
Robert Bast - Houston TX, US
Gabriel Hortobagyi - Bellaire TX, US
Lajos Pusztai - Pearland TX, US
Funda Meric - Houston TX, US
Aysegul Sahin - Houston TX, US
Gordon Mills - Houston TX, US

Assignee:

Millennium Pharmaceuticals, Inc. - Cambridge MA

International Classification:

A61K039/395
C12Q001/68
G01N033/574
C07H021/04
C12N009/00
C12P021/02
C12N005/06

US Classification:

424/155100, 435/006000, 435/069100, 435/183000, 435/320100, 435/325000, 530/388800, 536/023200, 435/007230

Abstract:

The invention relates to newly discovered nucleic acid molecules and proteins associated with breast cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human breast cancers are provided.

US Patent:

20050214831, Sep 29, 2005

Filed:

Feb 4, 2005

Appl. No.:

11/050926

Inventors:

John Monahan - Walpole MA, US
Manjula Gannavarapu - Acton MA, US
Sebastian Hoersch - Arlington MA, US
Shubhangi Kamatkar - Newton MA, US
Steven Kovats - Wilmington MA, US
Rachel Meyers - Newton MA, US
Michael Morrissey - Brighton MA, US
Peter Olandt - Watertown MA, US
Ami Sen - Framingham MA, US
Petter Veiby - Westborough MA, US
Gordon Mills - Houston TX, US
Robert Bast - Houston TX, US
Karen Lu - Houston TX, US
Rosemarie Schmandt - Houston TX, US
Xumei Zhao - Wayland MA, US
Karen Glatt - Natik MA, US

Assignee:

MILLENNIUM PHARMACEUTICALS, INC. - Cambridge MA

International Classification:

C12Q001/68
G01N033/574

US Classification:

435006000, 435007230

Abstract:

The invention relates to newly discovered nucleic acid molecules and proteins associated with ovarian cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human ovarian cancers are provided.

US Patent:

20070190550, Aug 16, 2007

Filed:

Dec 6, 2006

Appl. No.:

11/634620

Inventors:

Natalia Iartchouk - Wayland MA, US
Mark Ayers - Pennington NJ, US
Jeffrey Brown - Arlington MA, US
Robert Bast - Houston TX, US
Karen Lu - Houston TX, US
Gordon Mills - Houston TX, US

Assignee:

MILLENNIUM PHARMACEUTICALS, INC. - Cambridge MA
Board of Regents, The University of Texas System - Austin TX

International Classification:

C12Q 1/68
G01N 33/574
C12N 5/06
C07K 16/30

US Classification:

435006000, 435007230, 435338000, 530388800

Abstract:

The present invention is directed to the identification of markers that can be used to determine whether tumors are sensitive or resistant to a therapeutic agent. The present invention is also directed to the identification of therapeutic targets. The invention features a number of “sensitivity markers.” These are markers that are expressed in most or all cell lines that are sensitive to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are resistant to treatment with that agent. The invention also features a number of “resistance markers.” These are markers that are expressed in most or all cell lines that are resistant to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are sensitive to treatment with that agent.

US Patent:

20080311573, Dec 18, 2008

Filed:

Jun 25, 2007

Appl. No.:

11/821773

Inventors:

James Lillie - Weston MA, US
Manjula Gannavarapu - Acton MA, US
Karen Glatt - Natick MA, US
Sebastian Hoersch - Arlington MA, US
Shubhangi Kamatkar - Newton MA, US
Maureen Mertens - Stow MA, US
John E. Monahan - Walpole MA, US
Vickesh Myer - Harvard MA, US
Youzhen Wang - Newton MA, US
Yongyao Xu - Belmont MA, US
Xumei Zhao - Wayland MA, US
Rachel E. Meyers - Newton MA, US
Gabriel N. Hortobagyi - Bellaire TX, US
Lajos Pusztai - Houston TX, US
Funda Meric - Houston TX, US
Aysegul Sahin - Houston TX, US
Gordon B. Mills - Houston TX, US

Assignee:

MILLENNIUM PHARMACEUTICALS, INC. - Cambridge MA
Board of Regents, The University of Texas System - Austin TX

International Classification:

C12Q 1/68
G01N 33/574

US Classification:

435 6, 435 723

Abstract:

The invention relates to newly discovered nucleic acid molecules and proteins associated with breast cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human breast cancers are provided.

US Patent:

20090136961, May 28, 2009

Filed:

Nov 18, 2008

Appl. No.:

12/313196

Inventors:

Andrew I. Damokosh - West Hortford CT, US
Edwin A. Clark - Ashland MA, US
Karen Lu - Houston TX, US
Lynn Hartmann - Rochester MN, US
Gordon B. Mills - Houston TX, US

Assignee:

Millennium Pharmaceuticals, Inc. - Cambridge MA
Board of Regents - Austin TX
Mayo Foundation for Medical Education and Research - Rochester MN

International Classification:

C12Q 1/68

US Classification:

435 6

Abstract:

The present invention is directed to the identification of markers that can be used to determine whether ovarian cancer is sensitive or resistant to a therapeutic agent. In particular, the present invention is directed to the use of certain combinations of markers, wherein the expression of the markers correlates with sensitivity or resistance to a therapeutic agent. Thus, by examining the expression of the individual markers of a marker set, also referred to as the expression profile of the marker set, it is possible to determine whether a therapeutic agent, or combination of agents, will be most likely to reduce the growth rate of the ovarian cancer.